Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival

Autor:	Anoop K Enjeti, Naomi Mackinlay, Eva Yip, Luke Coyle, William Stevenson, Vicki Katsioulas, Christopher Arthur, Jake Shortt, Keith Fay, Matthew Greenwood, Anastasios Nalpantidis, Anthony Jeffrey, Ian Kerridge
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Low dose cytarabine 03 medical and health sciences 0302 clinical medicine Low-dose chemotherapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Thioguanine Aged Retrospective Studies Chemotherapy business.industry Remission Induction Complete remission Cytarabine Hematology Leukemia Myeloid Acute Treatment Outcome 030220 oncology & carcinogenesis Myeloid leukaemia Neoplasm Recurrence Local business 030215 immunology medicine.drug
Zdroj:	Leukemialymphoma. 61(4)
ISSN:	1029-2403
Popis:	The prognosis of AML in elderly patients is poor and research into novel therapeutic approaches is urgently needed. This study examined the use of low-dose chemotherapy with cytarabine and thioguanine administered in repetitive cycles in 62 elderly patients with newly diagnosed or relapsed/refractory AML. The overall response rate was 58% in the total cohort. Response rates (CR/CRi) were significantly higher in patients with newly diagnosed AML (74%) compared to patients with relapsed/refractory disease (25%
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad22a70d9cf72994e773555bc227ec4d https://pubmed.ncbi.nlm.nih.gov/31809629 Zobrazit plný text záznamu